Sophia Genetics Sa · NASDAQ:SOPH
Sophia Genetics Sa — J.P. Morgan Healthcare Conference 2023
32 slides from Sophia Genetics Sa's conference presentation, Jan 10, 2023
Slide 1: Building a data-driven world
#JPM CONF2023 J P M C O N F 2023 Building a data - driven world Dr. Jurgi Camblong Chief Executive Officer & Co - Founder
Slide 2: Cautionary Notices
Cautionary Notices This presentation contains statements that constitute forward - looking statements . All statements other than statements of historical facts contained in this presentation, including statements regarding our future results of operations and financial position, business strategy,
Slide 3: SOPHiA Genetics - Quick Snapshot
SOPHiA Genetics - Quick Snapshot 3 1 Headquarters: GENEVA & BOSTON 1. As of September 30, 2022, 2 . As of December 31, 2022 2
Slide 4: Cancer and rare diseases burden
4 1. By 2040 per The American Cancer Society, 2 . https:// www.rarediseasesinternational.org/ Cancer >25 Million New Cancer Cases per Year 1 Rare Diseases ~5% of the global population suffers from a rare disease 2
Slide 5: Heterogeneity Creates Massive Challenges
Heterogeneity Creates Massive Challenges 5 Sample prep h e t e r o g e n e i t y Sequencer h e t e r o g e n e i t y Limited clinically relevant outcomes Broad range of open - source bioinformatics approaches
Slide 6: We Find Signal in the Noise
We Find Signal in the Noise 6 Sample prep h e t e r o g e n e i t y Sequencer h e t e r o g e n e i t y Targeted clinically relevant outcomes Broad array of sophisticated algorithms 1. Patents pending
Slide 7: Multimodality Further Increases Complexity
Multimodality Further Increases Complexity 7 Amalgamation of siloed point solutions Uncorrelated clinical results Beyond genomics Radiomics • Proteomics • Metabolomics Digital Pathology
Slide 8: But our Algorithms are Up for the Challenge
But our Algorithms are Up for the Challenge 8 Personalized clinically relevant outcomes Broad array of proprietary algorithms Beyond genomics Radiomics • Proteomics • Metabolomics Digital Pathology 1. Patents pending
Slide 9: Introducing SOPHiA DDM Generation #2 | SOPHiA CarePath
Introducing SOPHiA DDM Generation #2 | SOPHiA CarePath 9
Slide 10: Notable Adoption of SOPHiA DDM Platform
Notable Adoption of SOPHiA DDM Platform 10 1 Represents active customers who have generated revenue through DDM platform usage or Alamut licenses as of September 30, 2022.
Slide 11: But the Total Addressable Market is Significant
But the Total Addressable Market is Significant 11
Slide 12: Clinical TAM Supported by a Broad Set of Disease Indications
Clinical TAM Supported by a Broad Set of Disease Indications 12 Disease Indications Somatic Oncology Liquid Biopsy He m O n c Hereditary Cancers Rare and Inherited Disorders
Slide 13: For a Variety of Customers Producing Data Locally
For a Variety of Customers Producing Data Locally 13 Central Labs C o m p r e h e n s i v e Cancer Centers Specialty Labs University Hospitals In - House Sequencing SOPHiA Patented Algorithms 1 C o n s u m p t i o n based model Interpret Data Targeted Clinical Outcomes Clinical Re p o r t i n g Uplo
Slide 14: Benefiting from a Rich Application Offering
Benefiting from a Rich Application Offering 14
Slide 15: Increased Account Penetration Crucial to Expand Strategy
Increased Account Penetration Crucial to Expand Strategy 15
Slide 16: A Look into a Customer's Expansion Journey
A Look into a Customer’s Expansion Journey 16 FN 1: Approximate values FN 2: Projected values as of November 30, 2022.
Slide 17: Customer Growth Accelerates as they get Larger
Importantly, Customer Growth Accelerates as they get Larger 17 Note: Based on recurring platform customers. FN 1: Represents CAGR of total tier revenue of customers with $100K+ in revenue and CAGR of total tier revenue of customers with $0 - $100K in revenue. FN 2: Projected values as of November 30
Slide 18: The Commercial Organization is at Scale
~1 0 NO R A M ~10 L A T A M ~5 APAC ~25 E M EA The Commercial Organization is at Scale ~40 Sales Operations & Customer Support 18 Sales Executives & Customer Success Executives
Slide 19: Strong Existing Partnership Ecosystem
Strong Existing Partnership Ecosystem 19
Slide 20: Strong Existing Partnership Ecosystem
Strong Existing Partnership Ecosystem With THREE meaningful new additions 20
Slide 21: Strong Existing Partnership Ecosystem
Strong Existing Partnership Ecosystem With THREE meaningful new additions 21
Slide 22: Strong Existing Partnership Ecosystem
Strong Existing Partnership Ecosystem With THREE meaningful new additions 22
Slide 23: BioPharma TAM is an Emerging Opportunity
BioPharma TAM is an Emerging Opportunity 23 Data Aggregating a growing number of data modalities with partnerships Development Powering predictive multimodal algorithms through CarePath Deployment Entering markets worldwide with new solutions via our network
Slide 24: Strong Early Traction Across BioPharma
Strong Early Traction Across BioPharma 24 PR E - AN D PO S T - AP P R O V AL PR E - AP P R O V AL PO S T - AP P R O V AL 1 AI Artificial Intelligence, 2 ML Machine Learning
Slide 25: Key Financial Metrics
750+ Total customers (1)(2) 380+ Recurring platform customers (1)(3) 2,750+ Users across network (1) ~260,000 Genomic profiles analyzed over last 12 months (1) ~$47.0M+ 2022 revenue guidance (4) 30% – 35% ‘21 - ‘22 constant currency core revenue growth (4) 63% | 65% Q1 – Q3 2022 IFRS gross margin |
Slide 26: Key Drivers for 2023 Performance
Key Drivers for 2023 Performance 26 Multimodality i.e. CarePath BioPharma i.e. Data & Liquid Biopsy Somatic On c o l o g y i.e. HRD, CGP 1 2 3
Slide 27: Thank You
2*- SOPHIA Thank You “ee GENETICS”
Slide 28: Appendix: Customer and Metric Disclosures
Appendix Customer Disclosure: Represents active customers who have generated revenue through DDM platform usage or Alamut licenses in the trailing 12 - month period as of Sept 30, 2022. Recurring Platform Customer Disclosure: Defined as the number of customers who accessed our platform through the d
Slide 29: Reconciliation of IFRS to Adjusted Gross Profit and Gross Profit Margin
29 Reconciliation of IFRS to Adjusted Gross Profit and Gross Profit Margin for the Nine Months Ended September 30, 2022 Amounts in USD thousands (unaudited) Nine months ended September 30, 2022 Revenue $34 , 176 Cost of revenue ( 12 , 552 ) Gross profit $21 , 624 Amortization of capitalized research
Slide 30: Summary Income Statement, Balance Sheet, & Cash Flow
30 Summary Income Statement, Balance Sheet, & Cash Flow 2021 Q1 Q2 Q3 Q4 2022 Q1 Q2 Q3 IFRS Revenue $8 , 976 $10 , 178 $10 , 359 $10 , 937 $10 , 861 $11 , 667 $11 , 648 Y - o - Y Growth 20% 72% 45% 40% 21% 15% 12% Current Period Constant Currency Impact 747 1,535 2,152 Constant Currency Revenue $8 ,
Slide 31: Notes to the Reconciliation of IFRS to Adjusted Financials
31 Notes to the Reconciliation of IFRS to Adjusted Financials (1) Amortization of capitalized research and development expenses consists of software development costs amortized using the straight - line method over an estimated life of five years. These expenses do not have a cash impact but remain
Slide 32: Platform Analysis Volume Has Been Growing Consistently
Platform Analysis Volume Has Been Growing Consistently Note: Represents statistic as of 09/30/2022. Includes recurring platform customer analyses volume. 2022 COVID - 19 Analyses Core Platform Analyses Total Analyses 32 44k 47k 52k 52k 57k 60k 60k 57k 11k 11k 9k 16k 17k 19k 19k 25k 26k 29k 29k 34k 3
SOPHiA GENETICS — J.P. Morgan Healthcare Conference 2023 on 6ix